Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Rocket Pharmaceuticals Inc (RCKT.N)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (US$) Price Target (US$) Rating
2019-03-2717.02-No Rating
2020-12-1558.6175.00Buy
2021-05-1142.0470.00Buy
2021-08-1132.3169.00Buy
2021-11-0935.4668.00Buy

Disclosures

  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
  • The equity analyst covering this company, a member of his or her team, or one of their household members has a long common stock position in this company.
  • Because this security exhibits higher-than-average volatility, the FSR has been set at 25% above the MRA for a Buy rating, and at -25% below the MRA for a Sell rating (compared with 6/-6% under the normal rating system).
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.